COVID-19:

How We're Keeping You Safe | What Patients & Families Need to Know

A photo of Rachid Drissi.

Director, Brain Tumor Center Translational Research Laboratory

Associate Professor, UC Department of Pediatrics

513-803-0674

513-636-3549

Biography & Affiliation

Academic Affiliation

Associate Professor, UC Department of Pediatrics

Divisions

Oncology, Cancer and Blood Diseases

Education

BS: University of Rouen, France, 1983.

MS: University of Rouen, France, 1984.

MS: University of Paris VI, France, 1988.

PhD: University of Paris VI, France, 1994.

Publications

Selected Publication

Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse. Zhang, L; He, X; Liu, X; Zhang, F; Huang, LF; Potter, AS; Xu, L; Zhou, W; Zheng, T; Luo, Z; et al. Cancer Cell. 2019; 36:302-318.e7.

International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma. Tsoli, M; Shen, H; Mayoh, C; Franshaw, L; Ehteda, A; Upton, D; Carvalho, D; Vinci, M; Meel, MH; van Vuurden, D; et al. Journal of Neuro-Oncology. 2019; 141:253-263.

Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors. Sengupta, S; Sobo, M; Lee, K; Kumar, SS; White, AR; Mender, I; Fuller, C; Chow, LM L; Fouladi, M; Shay, JW; et al. Molecular Cancer Therapeutics. 2018; 17:1504-1514.

Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. Hoffman, LM; van Zanten, SE M V; Colditz, N; Baugh, J; Chaney, B; Hoffmann, M; Lane, A; Fuller, C; Miles, L; Hawkins, C; et al. Journal of Clinical Oncology. 2018; 36:1963-1972.

BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma. Kumar, SS; Sengupta, S; Lee, K; Hura, N; Fuller, C; DeWire, M; Stevenson, CB; Fouladi, M; Drissi, R. Oncotarget. 2017; 8:62962-62975.

BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma. Kumar, SS; Sengupta, S; Lee, K; Hura, N; Fuller, C; DeWire, M; Stevenson, CB; Fouladi, M; Drissi, R. Oncotarget. 2017; 8:62962-62975.

A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. Salloum, R; Hummel, TR; Kumar, SS; Dorris, K; Li, S; Lin, T; Daryani, VM; Stewart, CF; Miles, L; Poussaint, TY; et al. Journal of Neuro-Oncology. 2016; 129:443-451.

A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas. Hummel, TR; Salloum, R; Drissi, R; Kumar, S; Sobo, M; Goldman, S; Pai, A; Leach, J; Lane, A; Pruitt, D; et al. Journal of Neuro-Oncology. 2016; 127:53-61.

New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Sturm, D; Orr, BA; Toprak, UH; Hovestadt, V; Jones, DT W; Capper, D; Sill, M; Buchhalter, I; Northcott, PA; Leis, I; et al. Cell. 2016; 164:1060-1072.

Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas. Dorris, K; Sobo, M; Onar-Thomas, A; Panditharatna, E; Stevenson, CB; Gardner, SL; DeWire, MD; Pierson, CR; Olshefski, R; Rempel, SA; et al. Journal of Neuro-Oncology. 2014; 117:67-76.